AACR 2026: AI Transforms Cancer Research Workflows

The 117th American Association for Cancer Research (AACR) Annual Meeting opened today in San Diego ^[1][2]. The Opening Plenary, titled "Precision, Partnership, Purpose," showcased how artificial intelligence (AI) has moved beyond experimental phases to become a core tool in oncology ^[2][3]. Experts from MIT and the Dana-Farber Cancer Institute highlighted the technology's role in modern medicine ^[1]. Researchers are now using AI to optimize clinical trial design and accelerate biomarker discovery ^[2][3]. This shift allows for more efficient spatial omics, which helps scientists understand the complex structure of tumors ^[1][2]. These advancements help doctors tailor personalized treatments for patients more accurately than before ^[3]. Dana-Farber scientists presented more than 50 research studies at this year’s conference ^[1]. The high volume of data-driven research reflects a growing partnership between computer scientists and oncologists ^[2][3]. This meeting continues to serve as a primary global hub for discussing the future of medical technology ^[2].